May Mangafodipir or Other SOD Mimetics Contribute to Better Care in COVID-19 Patients?
Viewpoint
[키워드] accompanied
acute respiratory syndrome
administration
Affect
aggregation
appear
approach
Better
Cardiopulmonary
characterized
chronic obstructive
clinical settings
clinical trial
Compound
Concentration
contrast agent
coronavirus
COVID-19
COVID-19 patient
disease
dismutase
double-blind
Efficacy
Endothelium
enzyme
expected
form
GC4419
inactivation
Inc
Inflammation
Inflammatory
Inflammatory response
inhibit
kill
life-threatening
low molecular weight
lung epithelial cell
magnetic resonance imaging
mangafodipir
manganese
manuscript
MnSOD
MnSOD-mimetic
MRI
Neutralizing
Nitrate
nitric oxide
organ
organs
Other
Patient
patients
pharmaceutical
pharmacological
Platelet
PROTECT
pulmonary disease
Randomized
resulting
risk
SARS-CoV-2
SARS-CoV-2 patient
SARS-CoV-2 patients
shown
submission
Superoxide
sustained
thrombosis
Treatment
vasoconstriction
widespread
[DOI] 10.3390/antiox9100971 PMC 바로가기 [Article Type] Viewpoint
[DOI] 10.3390/antiox9100971 PMC 바로가기 [Article Type] Viewpoint